Takeda To Highlight Rozerem Melatonin Receptor Mechanism Of Action
Executive Summary
Takeda's Rozerem promotions will highlight ramelteon's melatonin receptor activity and lack of abuse potential following FDA approval of the insomnia therapy
You may also be interested in...
Benzodiazepines, OTCs Are As Effective As Newer Rx Sleep Agents - Article
Newer insomnia treatments are no more effective than benzodiazepines and OTC antihistamines, Consumer Reports' August 2006 "Best Buy Drugs" report says
Benzodiazepines, OTCs Are As Effective As Newer Rx Sleep Agents - Article
Newer insomnia treatments are no more effective than benzodiazepines and OTC antihistamines, Consumer Reports' August 2006 "Best Buy Drugs" report says
Ambien Class Action Suit May Serve As Wake-Up Call For Competitors
A civil class action lawsuit in Manhattan federal court alleging that Sanofi-Aventis failed to adequately warn patients of the risk of sleep walking and sleep eating with Ambien (zolpidem) could open the door for other agents in the highly competitive sleep category